Laurence A Boxer M.D. Research Professor of Pediatrics
Professor of Pediatrics and Communicable Diseases
Professor of Pathology
[email protected]
Available to mentor
Steven W Pipe
Professor
-
von Drygalski A, Gomez E, Giermasz A, Castaman G, Key NS, Lattimore SU, Leebeek FWG, Miesbach WA, Recht M, Gut R, Dolmetsch R, Monahan PE, Le Quellec S, Pipe SW. Blood Adv, 2023 Oct 10; 7 (19): 5671 - 5679.Journal ArticleStable and durable factor IX levels in patients with hemophilia B over 3 years after etranacogene dezaparvovec gene therapy.
DOI:10.1182/bloodadvances.2022008886 PMID: 36490302 -
Schmidt M, Foster GR, Coppens M, Thomsen H, Dolmetsch R, Heijink L, Monahan PE, Pipe SW. Blood Adv, 2023 Sep 12; 7 (17): 4966 - 4969.Journal ArticleMolecular evaluation and vector integration analysis of HCC complicating AAV gene therapy for hemophilia B.
DOI:10.1182/bloodadvances.2023009876 PMID: 37352263 -
Pipe SW, Trzaskoma B, Minhas M, Lehle M, Ko RH, Gao L, Mahlangu J, Kempton CL, Kessler CM, Kruse-Jarres R. Res Pract Thromb Haemost, 2023 May; 7 (4): 100191Journal ArticleCorrigendum to 'Efficacy of emicizumab is maintained throughout dosing intervals for bleed prophylaxis' [Research and Practice in Thrombosis and Haemostasis, Volume 7, Issue 2, February 2023, 100077].
DOI:10.1016/j.rpth.2023.100191 PMID: 37538504 -
Srivastava A, Rangarajan S, Kavakli K, Klamroth R, Kenet G, Khoo L, You C-W, Xu W, Malan N, Frenzel L, Bagot CN, Stasyshyn O, Chang C-Y, Poloskey S, Qiu Z, Andersson S, Mei B, Pipe SW. Lancet Haematol, 2023 May; 10 (5): e322 - e332.Journal ArticleFitusiran prophylaxis in people with severe haemophilia A or haemophilia B without inhibitors (ATLAS-A/B): a multicentre, open-label, randomised, phase 3 trial.
DOI:10.1016/S2352-3026(23)00037-6 PMID: 37003278 -
Elsheikh E, Lavin M, Heck LA, Larkin N, Mullaney B, Doherty D, Kennedy M, Keenan C, Guest T, O'Mahony B, Fazavana J, Fallon PG, Preston RJS, Gormley J, Ryan K, O'Connell NM, Singleton E, Byrne M, McGowan M, Roche S, Doyle M, Crowley MP, O'Shea SI, Reipert BM, Johnsen JM, Pipe SW, Di Paola J, Turecek PL, O'Donnell JS, iPATH study group . J Thromb Haemost, 2023 May; 21 (5): 1123 - 1134.Journal ArticleHeterogeneity in the half-life of factor VIII concentrate in patients with hemophilia A is due to variability in the clearance of endogenous von Willebrand factor.
DOI:10.1016/j.jtha.2023.01.013 PMID: 36775768 -
Pipe SW, Arruda VR, Lange C, Kitchen S, Eichler H, Wadsworth S. Curr Gene Ther, 2023 23 (2): 81 - 95.Journal ArticleCharacteristics of BAY 2599023 in the Current Treatment Landscape of Hemophilia A Gene Therapy.
DOI:10.2174/1566523222666220914105729 PMID: 36111754 -
Ward SE, Guest T, Byrne C, Lopes P, O'Sullivan JM, Doherty D, O'Connell D, Gutierrez Llaneza S, Chion A, Fazavana J, Fallon PG, Preston RJS, Johnsen JM, Pipe SW, Turecek PL, O'Donnell JS, iPATH Study Group . Arterioscler Thromb Vasc Biol, 2023 Apr; 43 (4): 540 - 546.Journal ArticleMacrophage Galactose Lectin Contributes to the Regulation of FVIII (Factor VIII) Clearance in Mice-Brief Report.
DOI:10.1161/ATVBAHA.122.317807 PMID: 36727518 -
Pipe SW, Trzaskoma B, Minhas M, Lehle M, Ko RH, Gao L, Mahlangu J, Kempton CL, Kessler CM, Kruse-Jarres R. Res Pract Thromb Haemost, 2023 Feb; 7 (2): 100077Journal ArticleEfficacy of emicizumab is maintained throughout dosing intervals for bleed prophylaxis.
DOI:10.1016/j.rpth.2023.100077 PMID: 36908770
